MPO and heart failure: A double-blind phase 2a clinical study identified biomarker profiles associated with clinical outcomes in heart failure with preserved ejection fraction (HFpEF) and the levels of these biomarkers were downregulated after MPO inhibitor AZD4831 treatment, indicating that the effective inhibition of MPO is a promising strategy for HFpEF patients [234].